HAS2-Ezrin-ER axis plays a role in acquired antiestrogen resistance of ER-positive breast cancer.

ABSTRACT: The development of endocrine resistance is a major clinical problem in estrogen receptor-positive (ER⁺) breast cancer (BrCa) treatment, in which how cancer cells acquire resistance remains obscure. Hyaluronan synthase 2 (HAS2) is the most critical synthase in producing hyaluronan and is well known for its involvement in cancer growth, metabolism and metastasis. Recent evidence has proved that HAS2 is involved in cellular acquired resistance to drug therapy in BrCa. In this work, we first observed that HAS2 expression was decreased in the endocrine-resistant ER⁺ BrCa cells. Further knocking-out experiments confirmed that the loss of HAS2 in parental ER⁺ BrCa cells resulted in a following antiestrogen resistance. Next, we found that the HAS2-loss could induce

SUBMITTER: Sun X 

PROVIDER: S-EPMC9659586 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature